Attenuation of fear conditioning by antisense inhibition of brain corticotropin releasing factor-2 receptor

Molecular Brain Research

Volumn 89, Issue 1-2, 2001, Pages 29-40

  Ho, Siew Peng ^a   Takahashi, Lorey K ^a   Livanov, Valentin ^a   Spencer, Karen ^a   Lesher, Treena ^a   Maciag, Carla ^a   Smith, Mark A ^a   Rohrbach, Kenneth W ^a   Hartig, Paul R ^a   Arneric, Stephen P ^a  

^a DUPONT COMPANY   (United States)

Author keywords

Antisense oligonucleotide; Corticotropin releasing factor; CRF2 receptor; Fear conditioning; Shock induced freezing; Stress

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CORTICOTROPIN RELEASING FACTOR RECEPTOR; MESSENGER RNA;

ANIMAL TISSUE; ARTICLE; BEHAVIOR; BRAIN REGION; CONDITIONING; CONTROLLED STUDY; FEAR; FREEZING; GENE EXPRESSION; LOCOMOTION; MALE; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; RECEPTOR DENSITY; STRESS;

ANIMALS; CHO CELLS; CONDITIONING (PSYCHOLOGY); CRICETINAE; ELECTROSHOCK; FEAR; INJECTIONS, INTRAVENTRICULAR; MALE; OLIGONUCLEOTIDES, ANTISENSE; PAIN THRESHOLD; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; SEPTAL NUCLEI; STARTLE REACTION; STRESS;

ANIMALIA; RODENTIA;

EID: 0035906266     PISSN: 0169328X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-328X(01)00050-X     Document Type: Article

References (62)

1. Amygdalar participation in tonic ACTH secretion in the rat
2. The role of corticotropin-releasing factor in depression and anxiety disorders
3. Serial CSF corticotropin-releasing hormone levels and adrenocortical activity in combat veterans with post-traumatic stress disorder
4. Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behavior and are hypersensitive to stress
5. Control of ACTH secretion by the central nucleus of the amygdala: Implication of the serotonergic system and its relevance to the glucocorticoid delayed negative feedback mechanism
6. Neurobiology of corticotropin releasing factor (CRF) receptors and CRF-binding protein: Implications for the treatment of CNS disorders
7. Crouching as an index of fear
8. Predicting DNA duplex stability from the base sequence
9. 1 receptor mRNA expression
10. A functional neuroanatomy of anxiety and fear: Implications for the pathophysiology and treatment of anxiety disorders
11. Reduced anxiety-like and cognitive performance in mice lacking the corticotropin-releasing factor receptor 1
12. Footshock-induced freezing behavior in rats as a model of assessing anxiolytics
13. Antisense medicinal chemistry
14. Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotropin releasing hormone receptor-2
15. Corticotropin-releasing factor receptors: An overview
16. Physiological and behavioral responses to corticotropin-releasing factor administration: Is CRF a mediator of anxiety or stress responses?
17. Conditioned analgesia, defensive freezing and benzodiazepines
18. The discovery of 4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl) pyrazolo-[1,5-a]-pyrimidine: A corticotropin-releasing factor receptor (hcrf1) antagonist
19. Neurobiology of panic disorder
20. Intrastriatal and intraventricular injections of oligodeoxynucleotides in the rat brain: Tissue penetration, intracellular distribution and c-fos antisense effects
21. Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates
22. Serotonin reuptake inhibitors reduce conditioned fear stress-induced freezing behavior in rats
23. 2, receptors mediate anxiogenic-like behavior
24. Mapping of RNA accessible sites for antisense experiments with oligonucleotide libraries
25. RNA mapping: Selection of potent oligonucleotide sequences for the antisense experiment
26. Potent antisense oligonucleotides to the human multidrug resistance-1 mRNA are rationally selected by mapping RNA-accessible sites with oligonucleotide libraries
27. Modification of phosphorothioate oligonucleotides yields potent analogs with minimal toxicity for antisense experiments in the CNS
28. The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety
29. Antagonism of endogenous CRH systems attenuates stress-induced freezing behavior in rats
30. Fear-motivated behavior induced by prior shock experience is mediated by corticotropin-releasing hormone systems
31. Effects of amygdaloid lesions upon septal hyperemotionality in the rat
32. A sauvagine/corticotropin releasing factor receptor expressed in heart and skeletal muscle
33. Deletion of Crhr2 reveals an anxiolytic role for corticotropin-releasing hormone receptor-2
34. Molecular identification and analysis of a novel human corticotropin-releasing factor (CRF) receptor: The CRF2γ receptor
35. Role of the septum in the excitatory effect of corticotropin releasing hormone on the acoustic startle reflex
36. Corticotropin-releasing factor: Long-lasting facilitation of the acoustic startle reflex
37. Differential behavioral effects of chronic infusion of CRH1 and CRH2 receptor antisense oligonucleotides into the rat brain
38. Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain
39. A non peptidic corticotropin releasing factor receptor antagonist attenuates fever and exhibits anxiolytic-like activity
40. Antidepressant-like effects of CP-154,526, a selective CRF1 receptor antagonist
41. Effects of septal lesions on fear-potentiated startle, and on the anxiolytic effects of buspirone and diazepam
42. Lateral and medial septal lesions reduce anxiety in the plus maze and probe-burying tests
43. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase
44. Identification of a second corticotropin-releasing factor receptor gene and characterization of a cDNA expressed in heart
45. Post-traumatic stress disorder: Emotion, conditioning and memory
46. Modulation of learning and anxiety by corticotropin-releasing factor (CRF) and stress: Differential roles of CRF receptors 1 and 2
47. 2 receptors: Membrane homogenate and autoradiographic studies
48. Structural requirements for peptidic antagonists of the corticotropin-releasing factor receptor (CRFR): Development of CRFR2β-selective antisauvagine-30
49. Autoradiographic and in situ hybridization localization of corticotropin-releasing factor 1 and 2 receptors in nonhuman primate brain
50. Centrally administered oligodeoxynucleotides in rats: Occurrence of non-specific effects
51. ICV-CRH alters stress-induced freezing behavior without affecting pain sensitivity
52. Cortocotropin-releasing hormone receptor (type I) antisense targeting reduces anxiety
53. Corticotropin releasing factor receptor-1 deficient mice display decreased anxiety, impaired stress response and aberrant neuroendocrine development
54. Molecular properties of the CRF receptor
55. Overproduction of corticotropin-releasing factor in transgenic mice: A genetic model of anxiogenic behavior
56. Corticotropin releasing factor produces behavioral activation in rats
57. Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1
58. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and β-endorphin
59. Stress-induced behaviors require the corticotropin-releasing hormone (CRH) receptor, but not CRH
60. Chronic intrathecal infusion of phosphorothioate or phosdiester antisense oligonucleotides against cytokine responsive gene-2/IP in experimental allergic encephalomyelitis of Lewis rat
61. The role of the lateral septum in anxiolysis
62. Distribution of phosphodiester and phosphorothioate oligonucleotides in rat brain after intraventricular and intrahippocampal administration determined by in situ hybridization